Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

1.880 -0.080 (-4.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics

< Previous 1 2 3 4 5 6 7 Next >
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
4 Analysts Have This To Say About Sangamo Therapeutics
Via Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement. 
Via InvestorPlace
Peering Into Sangamo Therapeutics's Recent Short Interest
Via Benzinga
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
What's Going On With Sangamo Therapeutics Shares Tuesday?
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of... 
Via Benzinga
Exposures Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views
Via Benzinga
Topics Stocks
Exposures US Equities
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
From Sangamo Therapeutics, Inc.
Via Business Wire
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an... 
Via Benzinga
Exposures Product Safety
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Sangamo Therapeutics Stock Is Soaring
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for... 
Via Benzinga
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. 
Via InvestorPlace
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
Via Benzinga
Exposures Fossil Fuels
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate. 
Via Benzinga
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
From Sangamo Therapeutics, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.